Akros SCHK HK-U.S. Biotech Index

High importance is estimated due to the potential for significant market volatility following the report; Q2 2026 earnings release is scheduled.

Pfizer is scheduled to release its Q2 2026 earnings report before the market opens on August 4, 2026. Analysts forecast EPS of $0.68 and revenue of $14.45 billion, forecasted. High importance is estimated due to typical high volatility during earnings releases, scheduled.

Amgen is scheduled to report its Q2 2026 financial results after the market closes on August 4, 2026; analysts forecast an EPS of approximately $5.57-$5.60. This event is assigned Medium importance as earnings reports typically cause price shifts of 5% or more scheduled.

Merck to release its second-quarter 2026 financial results on August 4, 2026, before the market opens; low impact expected.

AbbVie announced on June 26, 2026, that it will report its second-quarter 2026 financial results on July 31, 2026, before the market opens, scheduled. High importance is estimated due to the potential for significant market volatility following the earnings report.

Bristol Myers Squibb is scheduled to announce its financial results for the second quarter of 2026 on July 30, 2026, before the market opens, followed by a conference call with executives. This is a recurring event with the potential for moderate stock price volatility based on results and guidance. This event is scheduled.

Ex-dividend date for the Q3 2026 dividend of $0.43 per share on July 24, 2026. Low importance is estimated as dividend events are routine and typically result in price adjustments equal to the dividend amount, scheduled.

Reported Q2 2026 earnings with adjusted EPS of $1.31, beating estimates of ~$1.28. Revenue was ~$12.5 billion, slightly missing estimates. The company raised its full-year 2026 adjusted EPS guidance to $5.45-$5.60. The stock rose over 11% in pre-market trading.

The U.S. FDA approved Lipfendra (enlicitide) on July 16, 2026, as the first once-daily oral PCSK9 inhibitor; high impact expected due to first-in-class status.

Johnson & Johnson reported Q2 2026 earnings on 2026-07-15, with revenue of $25.3 billion and adjusted EPS of $2.90, beating analyst expectations and raising full-year guidance.

Merck's partner Kelun-Biotech announced on July 14, 2026, that a Phase 3 trial of sac-TMT with KEYTRUDA met its primary endpoint; medium impact expected as it strengthens the oncology pipeline.